We would like to thank our shareholders for their continued support.

During the current interim consolidated accounting period, in Japan, although sales of Medical Gloves decreased, sales of Closed Drug Mixing/Infusion Systems—a key focus area—and Dysphagia-related products, for which demand is expanding, continued to grow. In overseas markets, while sales of AV Fistula Needles remained strong, sales of Apheresis Kits for North America and those related to Hemodialysis Business to China decreased.

As a result, net sales decreased by 1,614 million yen compared to the previous interim consolidated accounting period, amounting to 32,216 million yen (4.8% decrease from the same period of the previous fiscal year). This decrease was also due to a reduction in yen-denominated amounts resulting from the strong yen.

In accordance with our basic policy on profit distribution, we have decided to pay a dividend of 8.5 yen per share.

As a bridge between people and medicine, JMS will continue to create and provide "value" in the medical field in each country and region, and contribute to improving the quality of medical care and people's lives worldwide, while enhancing corporate value through sound business activities. Despite efforts to improve profitability, the Company recorded an operating loss of 19 million yen, compared to operating profit of 155 million yen in the previous interim consolidated accounting period, mainly due to decreased sales of mainstay overseas products and higher selling expenses. In addition, although the Company recorded equity in earnings of affiliates, foreign exchange losses resulted in an ordinary loss of 46 million yen (ordinary loss of 118 million yen in the previous interim consolidated accounting period). After income taxes, net loss attributable to owners of parent for the interim period amounted to 190 million yen (compared to an interim net loss of 258 million yen in the previous interim period).

We would like to ask our shareholders for their continued support and cooperation.

November 2025